Related Experiment Video

Updated: Oct 17, 2025

Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation
12:49

Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation

Published on: March 21, 2020

7.7K

Downregulation of lncRNA MEG3 is involved in Parkinson's disease

Hui Huang1, Suyue Zheng2, Mingwei Lu3

  • 1Department of Neurosurgery, the Second Affiliated Hospital of Nanchang University, Nanchang City, Jiangxi Province, PR, 330006, China.

Metabolic Brain Disease
|October 13, 2021
PubMed
Abstract

Insights

Long non-coding RNA MEG3 is downregulated in Parkinson's disease (PD) patients. This study suggests MEG3 influences LRRK2 expression, impacting cell viability and apoptosis in PD.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Genetics

Background:

  • Long non-coding RNA (lncRNA) MEG3 is implicated in human cancers.
  • The specific role of MEG3 in Parkinson's disease (PD) remains largely unexplored.

Purpose of the Study:

  • To investigate the involvement and function of lncRNA MEG3 in Parkinson's disease.
  • To explore the relationship between MEG3 and leucine-rich repeat kinase 2 (LRRK2) in PD pathogenesis.

Main Methods:

  • Quantitative real-time PCR (RT-qPCR) to measure MEG3 and LRRK2 expression in PD patients and controls.
  • Receiver Operating Characteristic (ROC) curve analysis for diagnostic assessment.
  • In vitro cell transfection studies to examine MEG3-LRRK2 interactions, cell apoptosis, and viability.

Main Results:

  • MEG3 expression was significantly downregulated in PD patients compared to healthy controls.
  • MEG3 downregulation was also observed in MPP+ treated SH-SY5Y cells, a cellular model of PD.
  • Overexpression of MEG3 increased LRRK2 expression and improved cell viability while inhibiting apoptosis in MPP+-treated SH-SY5Y cells.

Conclusions:

  • lncRNA MEG3 is downregulated in Parkinson's disease.
  • MEG3 may regulate LRRK2 expression, thereby influencing cell viability and apoptosis in PD.
  • MEG3 represents a potential therapeutic target for Parkinson's disease.
Keywords:
Leucine-rich repeat kinase 2Parkinson’s diseaselncRNA MEG3

More Related Videos

Lentiviral Vector Platform for the Efficient Delivery of Epigenome-editing Tools into Human Induced Pluripotent Stem Cell-derived Disease Models13:47

Lentiviral Vector Platform for the Efficient Delivery of Epigenome-editing Tools into Human Induced Pluripotent Stem Cell-derived Disease Models

Published on: March 29, 2019

9.9K
Rab10 Phosphorylation Detection by LRRK2 Activity Using SDS-PAGE with a Phosphate-binding Tag08:55

Rab10 Phosphorylation Detection by LRRK2 Activity Using SDS-PAGE with a Phosphate-binding Tag

Published on: December 14, 2017

15.5K

Related Concept Videos

Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
40.5K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
22.4K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.0K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
840
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
444